This activity is jointly provided by Global Education Group and PlatformQ Health Education, LLC, in collaboration with the National Organization for Rare Disorders, Inc. (NORD) and Myasthenia Gravis Foundation of America, Inc.

ACKNOWLEDGEMENT

This activity is supported by an educational grant from argenx.

DATE OF RELEASE/EXPIRATION

This activity was released on September 9, 2022 and is valid until September 9, 2023. Requests for credit must be made no later than September 9, 2023.

TARGET AUDIENCE

The intended audience for this activity are neurology, neuromuscular, neuroimmunology, and neuro-ophthalmology specialists, along with advanced practice neurology practitioners, such as neurology NPs, neurology PAs, and clinical pharmacists.

STATEMENT OF NEED/PROGRAM OVERVIEW

The treatment paradigm for generalized myasthenia gravis (gMG) is changing rapidly with the availability of new antibody tests and targeted treatment options. The treatment landscape for gMG is shifting from reliance on nonspecific immunosuppressants to personalized targeted approaches that address the underlying pathophysiology and achieve disease remission. More than ever, clinicians must engage their patients with gMG in shared decision-making to ensure treatment selection aligns with patient characteristics, preferences, and goals.

The 60-minute CME-certified activity, “Rationale and Evidence for Individualized Treatment Decisions in gMG,” will review recently approved and emerging treatment options that have shown a more rapid onset of effect and improved disease control than traditional treatments. Expert panelists will review clinically important gMG outcomes measures and compare the safety and efficacy profiles of both current and emerging treatments for patients with gMG.

EDUCATIONAL OBJECTIVES

After completing this activity, the participant should be better able to:

• Describe the burden of gMG disease and its treatment with traditional options
• Summarize the targeted mechanisms of action, efficacy, safety, and place in therapy of new and emerging treatments for gMG with a focus on FcRn-receptor antagonists
• Describe how accounting for patient characteristics (autoantibody status, MG presentation), preferences, desire to maintain autonomy, quality of life, and treatment goals can impact treatment selection

PHYSICIAN ACCREDITATION STATEMENT

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and PlatformQ Health Education, LLC. Global is accredited by the ACCME to provide continuing medical education for physicians.

PHYSICIAN CREDIT DESIGNATION

Global Education Group designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ESTIMATED TIME TO COMPLETE

This activity should take approximately 60 minutes to complete.

INSTRUCTIONS TO RECEIVE CREDIT

In order to receive credit for this activity, the participant must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a score of 70% on the post-test.

HARDWARE/SOFTWARE REQUIREMENTS

Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.

FEE INFORMATION & REFUND/CANCELLATION POLICY

There is no fee for this educational activity.

DISCLOSURE OF CONFLICTS OF INTEREST

Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

Name of Faculty or Presenter	Reported Financial Relationship
James F. Howard Jr., MD Professor of Neurology, Medicine and Allied Health School of Medicine University of North Carolina at Chapel Hill Chapel Hill, NC	Consulting Fee (e.g., Advisory Board): Alexion Pharmaceuticals, argenx, F. Hoffmann-LaRoche Ltd, Immunovant, Ra Pharmaceuticals (now UCB), Regeneron Pharmaceuticals, Sanofi, US, and Viela Bio Inc (now Horizon Therapeutics) Contracted Research: Alexion Pharmaceuticals, argenx, Cartesian Therapeutics, Millennium Pharmaceuticals, Ra Pharmaceuticals (now UCB) Honoraria: Alexion Pharmaceuticals, argenx, F. Hoffmann-LaRoche Ltd, Immunovant, Ra Pharmaceuticals (now UCB), Regeneron Pharmaceuticals, Sanofi, US, Viela Bio Inc (now Horizon Therapeutics) Stock Option Holder: General Electric, GlaxoSmithKline, Johnson & Johnson, and Pfizer
Nicholas J. Silvestri, MD, FAAN Associate Professor of Neurology University at Buffalo Jacobs School of Medicine & Biomedical Sciences Buffalo, NY	Consulting Fee (e.g., Advisory Board): argenx, Avilar, Alexion, Immunovant, and UCB
Kimberly Baggett Patient Panelist	Nothing to disclose

The planners and managers have the following relevant financial relationships with ineligible companies:

Name of Planner or Manager	Reported Financial Relationship
Lindsay Borvansky	Nothing to disclose
Andrea Funk	Nothing to disclose
Liddy Knight	Nothing to disclose
Ashley Cann	Nothing to disclose
Lauren Sinclair	Nothing to disclose
Carole Drexel, PhD	Nothing to disclose
Colleen Heffner	Nothing to disclose
Stephanie Puccio	Nothing to disclose

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and PlatformQ Health Education, LLC do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER:

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

CONTACT INFORMATION

Accreditation Support:

For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com

Technical Support:

For any technical issues or issues with your CME Certificate, please contact NeuroSeriesLive.com at 877-394-1306 or at Support@NeuroSeriesLive.com.